MX2021007393A - Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. - Google Patents
Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf.Info
- Publication number
- MX2021007393A MX2021007393A MX2021007393A MX2021007393A MX2021007393A MX 2021007393 A MX2021007393 A MX 2021007393A MX 2021007393 A MX2021007393 A MX 2021007393A MX 2021007393 A MX2021007393 A MX 2021007393A MX 2021007393 A MX2021007393 A MX 2021007393A
- Authority
- MX
- Mexico
- Prior art keywords
- high concentration
- antibody
- protein solution
- formulation containing
- containing high
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente divulgación proporciona anticuerpos anti-VEGF formulados como alta concentración, composiciones farmacéuticas acuosas, adecuadas para una inyección, con preferencia una inyección intravítrea. Las composiciones farmacéuticas acuosas son útiles para el suministro de una alta concentración del ingrediente activo del anticuerpo a un paciente sin altos niveles de agregación de anticuerpos y sin un alto nivel de material particulado sub-visible. Una composición acuosa de la divulgación comprende un anticuerpo que tiene una concentración de al menos 50 mg/mL. Una composición farmacéutica acuosa de la divulgación incluye un azúcar, un agente tamponador, y un surfactante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781003P | 2018-12-18 | 2018-12-18 | |
| PCT/IB2019/060859 WO2020128792A1 (en) | 2018-12-18 | 2019-12-16 | Protein solution formulation containing high concentration of an anti-vegf antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007393A true MX2021007393A (es) | 2021-09-23 |
Family
ID=69165422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007393A MX2021007393A (es) | 2018-12-18 | 2019-12-16 | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11945859B2 (es) |
| EP (1) | EP3897714A1 (es) |
| JP (2) | JP7089121B2 (es) |
| KR (1) | KR20210106476A (es) |
| CN (1) | CN113194993A (es) |
| AR (1) | AR117707A1 (es) |
| AU (1) | AU2019407063B2 (es) |
| BR (1) | BR112021011290A2 (es) |
| CA (1) | CA3119241A1 (es) |
| CL (1) | CL2021001587A1 (es) |
| CO (1) | CO2021007830A2 (es) |
| CR (1) | CR20210318A (es) |
| EC (1) | ECSP21043639A (es) |
| IL (1) | IL283456A (es) |
| JO (1) | JOP20210152A1 (es) |
| MX (1) | MX2021007393A (es) |
| PE (1) | PE20211602A1 (es) |
| SG (1) | SG11202104653XA (es) |
| TW (1) | TW202031289A (es) |
| WO (1) | WO2020128792A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102076716A (zh) | 2008-06-25 | 2011-05-25 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 抑制TNFα的稳定和可溶的抗体 |
| DK2307458T3 (en) | 2008-06-25 | 2018-07-16 | Esbatech Alcon Biomed Res Unit | Humanization of rabbit antibodies using a universal antibody framework |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| MX347972B (es) | 2008-06-25 | 2017-05-22 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles que inhiben el vegf. |
| CN102076716A (zh) | 2008-06-25 | 2011-05-25 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 抑制TNFα的稳定和可溶的抗体 |
| DK2307458T3 (en) | 2008-06-25 | 2018-07-16 | Esbatech Alcon Biomed Res Unit | Humanization of rabbit antibodies using a universal antibody framework |
| WO2012076670A2 (en) * | 2010-12-10 | 2012-06-14 | Novartis Ag | Antibody formulation |
| US20140213814A1 (en) | 2011-06-16 | 2014-07-31 | Lonza Braine S.A. | Process For Extraction Of Peptides And Its Application In Liquid Phase Peptide Synthesis |
| SG194932A1 (en) | 2011-06-30 | 2013-12-30 | Genentech Inc | Anti-c-met antibody formulations |
| US20140004131A1 (en) * | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| TWI761959B (zh) * | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| MX2020009140A (es) | 2018-03-16 | 2020-09-28 | Novartis Ag | Metodos para el tratamiento de enfermedades oculares. |
-
2019
- 2019-12-16 MX MX2021007393A patent/MX2021007393A/es unknown
- 2019-12-16 WO PCT/IB2019/060859 patent/WO2020128792A1/en unknown
- 2019-12-16 AR ARP190103687A patent/AR117707A1/es unknown
- 2019-12-16 SG SG11202104653XA patent/SG11202104653XA/en unknown
- 2019-12-16 PE PE2021000916A patent/PE20211602A1/es unknown
- 2019-12-16 CN CN201980081759.8A patent/CN113194993A/zh active Pending
- 2019-12-16 BR BR112021011290A patent/BR112021011290A2/pt unknown
- 2019-12-16 CA CA3119241A patent/CA3119241A1/en active Pending
- 2019-12-16 CR CR20210318A patent/CR20210318A/es unknown
- 2019-12-16 EP EP19836538.9A patent/EP3897714A1/en active Pending
- 2019-12-16 US US16/715,580 patent/US11945859B2/en active Active
- 2019-12-16 KR KR1020217021741A patent/KR20210106476A/ko unknown
- 2019-12-16 JP JP2021534608A patent/JP7089121B2/ja active Active
- 2019-12-16 AU AU2019407063A patent/AU2019407063B2/en active Active
- 2019-12-16 TW TW108146070A patent/TW202031289A/zh unknown
- 2019-12-16 JO JOP/2021/0152A patent/JOP20210152A1/ar unknown
-
2021
- 2021-05-25 IL IL283456A patent/IL283456A/en unknown
- 2021-06-15 CO CONC2021/0007830A patent/CO2021007830A2/es unknown
- 2021-06-16 EC ECSENADI202143639A patent/ECSP21043639A/es unknown
- 2021-06-16 CL CL2021001587A patent/CL2021001587A1/es unknown
-
2022
- 2022-04-20 JP JP2022069588A patent/JP2022105056A/ja active Pending
-
2024
- 2024-02-16 US US18/444,288 patent/US20240182554A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022105056A (ja) | 2022-07-12 |
| EP3897714A1 (en) | 2021-10-27 |
| ECSP21043639A (es) | 2021-07-30 |
| CO2021007830A2 (es) | 2021-06-21 |
| IL283456A (en) | 2021-07-29 |
| JP7089121B2 (ja) | 2022-06-21 |
| JOP20210152A1 (ar) | 2023-01-30 |
| AU2019407063A1 (en) | 2021-05-27 |
| PE20211602A1 (es) | 2021-08-18 |
| SG11202104653XA (en) | 2021-07-29 |
| US20200190179A1 (en) | 2020-06-18 |
| CN113194993A (zh) | 2021-07-30 |
| US11945859B2 (en) | 2024-04-02 |
| KR20210106476A (ko) | 2021-08-30 |
| TW202031289A (zh) | 2020-09-01 |
| JP2022513253A (ja) | 2022-02-07 |
| CA3119241A1 (en) | 2020-06-25 |
| AU2019407063B2 (en) | 2024-07-04 |
| WO2020128792A1 (en) | 2020-06-25 |
| CL2021001587A1 (es) | 2022-02-11 |
| AR117707A1 (es) | 2021-08-25 |
| US20240182554A1 (en) | 2024-06-06 |
| CR20210318A (es) | 2021-07-14 |
| BR112021011290A2 (pt) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500844A1 (en) | Stable protein solution formulation containing high concentration of an anti-vegf antibody | |
| AU2016204371A1 (en) | Lyophilised and aqueous anti-CD40 antibody formulations | |
| HRP20120903T1 (hr) | Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela | |
| WO2012076670A3 (en) | Antibody formulation | |
| WO2010100200A3 (en) | Lyophilised antibody formulation | |
| PH12014502778B1 (en) | Antibody formulation | |
| GEP20125628B (en) | Pharmaceutical compositions containing antagonist anti-cd40 antibody | |
| MX2009010179A (es) | Formulaciones estables de anticuerpo. | |
| EA202193240A1 (ru) | Стабилизированные составы, содержащие анти-angptl3 антитела | |
| MX2021007393A (es) | Formulacion de solucion de proteinas que contiene una alta concentracion de un anticuerpo anti-vegf. | |
| EP3156071A1 (en) | Stable aqueous adalimumab preparation | |
| AR102572A1 (es) | Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf | |
| JP6204349B2 (ja) | 注射剤用組成物 | |
| RU2019125947A (ru) | Новые стабильные композиции для fxia антител | |
| TH151334A (th) | สูตรผสมเชิงเภสัชกรรมที่เข้มข้นสูง, ซึ่งเสถียรของแอนติ-CD20 แอนติบอดี (anti-CD20 antibody) | |
| TH120955A (th) | การตั้งสูตรตำรับแอนติบอดีที่ต้านเอเบต้า |